Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_67bf280a23817fdc0f1cd4dc93ff0b98 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-185 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05 |
filingDate |
2019-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0bbef9301d13fcd7e08d9870245798b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1c5b597cc5f4c8cb407af6f83f0b3cb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e0daf690aa9ded0a9b899d40a57e1ba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5dbec8d2885616a28a8de0ab0783e60 |
publicationDate |
2020-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2020069608-A1 |
titleOfInvention |
Use of cannabinoids in the treatment of epilepsy |
abstract |
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs). |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10709673-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11766411-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11633369-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10849860-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11446258-B2 |
priorityDate |
2014-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |